ALL STEM CELLS

Celution : Cell Therapy at the Point-of-Care

Celution System
A surgeon harvests a small amount of adipose tissue from the patient, or fat as it is more commonly know. The surgeon then places the fat into the Celution system. The system then processes the fat and in 90 minutes provides the surgeon with a five cc heterogeneous population of the patient’s own regenerative cells to be used to treat an ischemic disease. This five cc syringe of autologous regenerative cells can be mixed back with the patients fat cells to create a cell-enriched fat graft, or used independently depending on the presenting case. Celution system is a combination of capital equipment and a per-patient consumable set. The system was designed for the operating room or cardiac cath lab and designed to vertically integrate into the operating room workflow. The system is the culmination of a decade of research and development that is now being used through Europe, Japan, the US and India.
Celution has been reviewed and approved for use in Europe by CE Mark. The Celution 800/CRS System is indicated for:

Plastic & Reconstructive Procedures to replace, repair, reconstruct, or augment
Surgical soft tissue defects (defect up to 150 mL in size and augment up to 260 mL of volume), Such as those seen in the breast due to mastectomies and lumpectomies
Liposuction defects, such as those seen in the abdomen, back, thighs and buttocks
Congenital asymmetry of soft tissues, such as those seen in the breast, buttocks and face
Soft tissue wasting disorders, such as those affecting the hands and face
The Celution 800/GP System is indicated for:

General surgery procedures to facilitate healing in: rectal and vaginal fistulae in Crohn’s disease
Adipose (fat) tissue-derived regenerative cells (ADRCs) obtained using the Celution System demonstrated a statistically significant improvement in cardiac functional capacity (MVO2) at 18 months in PRECISE trial for chronic myocardial ischemia. New data from this trial were presented at the American Heart Association Scientific Sessions 2010 in Chicago by Co-Principal Investigator Emerson C. Perin, MD, PhD, Director, Clinical Research for Cardiovascular Medicineand Medical Director, Stem Cell Centre, Texas Heart Institute.

Source : financialexpress.com